Data spans 10 therapies across 10 types of
cancer
Pfizer Inc. (NYSE:PFE) will present data across its
industry-leading oncology portfolio, covering multiple tumor types
and mechanisms of action at the 55th Annual Meeting of the American
Society of Clinical Oncology (ASCO) in Chicago from May 31-June 4,
2019. Data will highlight Pfizer’s cutting-edge approach, expertise
in precision medicine and work in immunotherapy combinations,
including company-sponsored and collaborative research studies.
“The data presented at this year’s ASCO showcase our continued
commitment to follow the science, whether it’s expanding our
approved medicines for breast and prostate cancers into new
populations and lines of therapy, or exploring the important role
of biomarkers and immunotherapy combinations,” said Dany Habr,
M.D., Chief Medical Officer, Pfizer Oncology. “We look forward to
both sharing our exciting data in these and other tumor types, as
well as connecting with our research partners to determine how we
can continue to work collaboratively to bring transformative
therapies to our cancer patients.”
The research to be presented includes new insights on Pfizer’s
marketed therapies, including IBRANCE® (palbociclib), XTANDI®
(enzalutamide), TALZENNA® (talazoparib), BOSULIF® (bosutinib),
INLYTA® (axitinib) and BAVENCIO® (avelumab), which represent Pfizer
Oncology’s long-standing legacy of developing innovative therapies
for patients in need, as well as its ongoing commitment to
addressing the needs of cancer patients across gender, ethnicity
and tumor type. For example, Pfizer will present real-world data on
the use of IBRANCE for the treatment of men with metastatic breast
cancer (MBC).
“At this year’s ASCO, I am particularly excited that we’ll share
data from new initiatives such as the oral presentation of
talazoparib in breast cancer or other solid tumors. This builds on
a productive year with the approval of four new oncology
treatments, three biosimilars and three new indications, including
one based on real-world evidence,” said Chris Boshoff, M.D., Ph.D.,
Chief Development Officer, Oncology, Pfizer Global Product
Development. “We are proud to have one of the broadest oncology
portfolios in the industry, and a research philosophy that puts
patients first, embraces new approaches and showcases innovative
thinking.”
Key Pfizer-sponsored, investigator-sponsored and collaborative
research abstracts leveraging the depth of Pfizer’s scientific
advances include:
- A poster presentation on real-world
evidence of male breast cancer patients treated with IBRANCE in
combination with endocrine therapy (Abstract 1055).
- An external investigator-sponsored oral
presentation on a Phase 2 trial examining TALZENNA beyond BRCA,
specifically as monotherapy in BRCA1 and BRCA2 wild-type patients
with advanced HER2-negative breast cancer or other solid tumors
with a mutation in homologous recombination (HR) pathway genes
(Investigator-sponsored abstract 3006).
- Biomarker analyses from JAVELIN Renal
101 that studied BAVENCIO plus INLYTA vs. sunitinib in advanced
renal cell carcinoma (aRCC) (Abstract 101).
- An external collaborative research
presentation on genomic markers of early progression on fulvestrant
with or without IBRANCE for ER+ advanced breast cancer in the
PALOMA-3 trial (Collaborative research abstract 1010).
Details for the Pfizer-sponsored, investigator-sponsored and
collaborative research oral presentations are below:
Title/Abstract
Number Date/Time (CDT)
Location (Abstract 101)
Biomarker Analyses from JAVELIN Renal 101:
Avelumab + Axitinib (A + Ax) vs Sunitinib (S) in Advanced Renal
Cell Carcinoma (aRCC)
Choueiri TK
Saturday, June 1
8:12 AM - 8:24 AM
Hall D1 (Abstract 1010)
Genomic Markers of Early Progression on
Fulvestrant with or without Palbociclib for ER+ Advanced Breast
Cancer in the PALOMA-3 Trial
O’Leary B
Saturday, June 1
3:12 PM - 3:24 PM
Hall D1 (Abstract 3006)
Talazoparib Beyond BRCA: A Phase II Trial
of Talazoparib Monotherapy in BRCA1 and BRCA2 Wild-Type Patients
with Advanced HER2-Negative Breast Cancer or Other Solid Tumors
with a Mutation in Homologous Recombination (HR) Pathway Genes
Gruber J
Monday, June 3
10:00 AM - 10:12 AM
S406 (Abstract 5502)
Phase 2, Two-Group, Two-Stage Study of
Avelumab in Patients (Pts) with Microsatellite Stable (MSS),
Microsatellite Instable (MSI) and Polymerase Epsilon (POLE) Mutated
Recurrent/Persistent Endometrial Cancer (EC)
Konstantinopoulos PA
Monday, June 3
1:39 PM - 1:51 PM
S406 (Abstract 1007)
A Randomized Phase II Study of Palbociclib
plus Exemestane with GNRH Agonist versus Capecitabine in
Premenopausal Women with Hormone Receptor-Positive Metastatic
Breast Cancer (KCSG-BR 15-10, NCT02592746)
Park YH
Tuesday, June 4
11:45 AM - 11:57 AM
Hall D1
Please see a complete list of Pfizer-sponsored abstracts
featuring data on our broad pipeline of biologics and small
molecules at https://www.pfizer.com/news/press-kits/oncology.
Learn more about how developing new medicines and supporting
people with cancer is personal for Pfizer Oncology at
https://www.pfizer.com/news/press-kits/oncology.
Please see full US Prescribing
Information and Medication Guide for BAVENCIO®
(avelumab) available at http://www.Bavencio.com.
Please see full Prescribing Information for INLYTA® (axitinib)
at www.Inlyta.com.
Please see full Prescribing Information for BOSULIF® (bosutinib)
at www.Bosulif.com.
Please see full Prescribing Information for IBRANCE®
(palbociclib) at www.Ibrance.com.
Please see full Prescribing Information for TALZENNA®
(talazoparib) at www.Talzenna.com.
Please see full Prescribing Information for XTANDI®
(enzalutamide) at www.Xtandi.com.
About Pfizer OncologyAt Pfizer Oncology, we are committed
to advancing medicines wherever we believe we can make a meaningful
difference in the lives of patients. Today, Pfizer Oncology has an
industry-leading portfolio of 18 approved innovative cancer
medicines and biosimilars across more than 20 indications,
including breast, prostate, kidney, lung and hematology. Pfizer
Oncology is striving to change the trajectory of cancer.
Pfizer Inc: Working together for a healthier
world®At Pfizer, we apply science and our global
resources to bring therapies to people that extend and
significantly improve their lives. We strive to set the standard
for quality, safety and value in the discovery, development and
manufacture of health care products. Our global portfolio includes
medicines and vaccines as well as many of the world's best-known
consumer health care products. Every day, Pfizer colleagues work
across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared
diseases of our time. Consistent with our responsibility as one of
the world's premier innovative biopharmaceutical companies, we
collaborate with health care providers, governments and local
communities to support and expand access to reliable, affordable
health care around the world. For more than 150 years, we have
worked to make a difference for all who rely on us. We routinely
post information that may be important to investors on our website
at www.pfizer.com. In addition, to learn more, please visit us
on www.pfizer.com and follow us on Twitter at
@Pfizer and @Pfizer_News, LinkedIn, YouTube, and
like us on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is
as of May 15, 2019. Pfizer assumes no obligation to update
forward-looking statements contained in this release as the result
of new information or future events or developments.
This release contains forward-looking information about Pfizer
Oncology’s marketed oncology portfolio, including, among others,
BAVENCIO (avelumab), INLYTA (axitinib), IBRANCE (palbociclib),
TALZENNA (talazoparib) and XTANDI (enzalutamide), including their
potential benefits, that involves substantial risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. Risks and
uncertainties include, among other things, uncertainties regarding
the commercial success of Pfizer’s oncology portfolio; the
uncertainties inherent in research and development, including,
without limitation, the ability to meet anticipated clinical trial
commencement and completion dates and regulatory submission dates,
as well as the possibility of unfavorable clinical trial results,
including unfavorable new clinical data and additional analyses of
existing clinical data; the risk that clinical trial data are
subject to differing interpretations, and, even when we view data
as sufficient to support the safety and/or effectiveness of a
product candidate, regulatory authorities may not share our views
and may require additional data or may deny approval altogether;
whether regulatory authorities will be satisfied with the design of
and results from our clinical studies; whether and when drug
applications may be filed in any jurisdictions for any potential
indication for Pfizer’s oncology products and product candidates;
whether and when applications that are pending or any such other
applications that may be filed for any of Pfizer’s oncology
products and product candidates may be approved by regulatory
authorities, which will depend on the assessment by such regulatory
authorities of the benefit-risk profile suggested by the totality
of the efficacy and safety information submitted, and, if approved,
whether any such oncology products will be commercially successful;
decisions by regulatory authorities regarding labeling and other
matters that could affect the availability or commercial potential
of Pfizer’s oncology products and product candidates; and
competitive developments. A further description of risks and
uncertainties can be found in Pfizer’s Annual Report on Form 10-K
for the fiscal year ended December 31, 2018 and in its subsequent
reports on Form 10-Q, including in the sections thereof captioned
“Risk Factors” and “Forward-Looking Information and Factors That
May Affect Future Results”, as well as in its subsequent reports on
Form 8-K, all of which are filed with the U.S. Securities and
Exchange Commission and available at www.sec.gov and
www.pfizer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190515005940/en/
Pfizer Media:Jessica Smith(212)
733-6213Jessica.M.Smith@pfizer.com
Pfizer Investors:Ryan Crowe(212)
733-8160Ryan.Crowe@pfizer.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2023 to Sep 2024